Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

Mark Dmytruk Biography and Net Worth

Insider of Ginkgo Bioworks

Mark joined Ginkgo in November 2020 with 25 years of finance and executive leadership experience, primarily in the life sciences and diagnostics industries. Prior to Ginkgo, Mark held several executive roles at Syneos Health (formerly INCResearch / inVentiv Health), a $4.5B revenue global CRO serving the biopharma industry, including EVP Corporate Strategy & Development and President, Patient Outcomes division. Prior to Syneos, Mark was at Thermo Fisher Scientific from 2001 - 2011. As VP Corporate Development, Mark led the company’s M&A function, contributing to its industry-changing strategy and transformational growth. He was also VP Finance for the Athena Diagnostics business unit prior to its sale to Quest Diagnostics. Mark began his career at Ernst & Young in Canada. He holds a Bachelor of Commerce from the University of Alberta and an MBA from the Sloan School of Management at MIT.

What is Mark E. Dmytruk's net worth?: The estimated net worth of Mark E. Dmytruk is at least $6.63 million as of May 2nd, 2024. Mr. Dmytruk owns 925,400 shares of Ginkgo Bioworks stock worth more than $6,630,491 as of November 22nd. This net worth evaluation does not reflect any other assets that Mr. Dmytruk may own. Additionally, Mr. Dmytruk receives a salary of $476,500.00 as Insider at Ginkgo Bioworks. Learn More about Mark E. Dmytruk's net worth.
How old is Mark E. Dmytruk?: Mr. Dmytruk is currently 52 years old. There are 2 older executives and no younger executives at Ginkgo Bioworks. Learn More on Mark E. Dmytruk's age.
What is Mark E. Dmytruk's salary?: As the Insider of Ginkgo Bioworks Holdings, Inc., Mr. Dmytruk earns $476,500.00 per year. Learn More on Mark E. Dmytruk's salary.
How do I contact Mark E. Dmytruk?: The corporate mailing address for Mr. Dmytruk and other Ginkgo Bioworks executives is 955 Fifth Avenue, New York NY, 10075. Ginkgo Bioworks can also be reached via phone at 877-442-5362 and via email at [email protected]. Learn More on Mark E. Dmytruk's contact information.
Has Mark E. Dmytruk been buying or selling shares of Ginkgo Bioworks?: Mark E. Dmytruk has not been actively trading shares of Ginkgo Bioworks within the last three months. Most recently, Mark E. Dmytruk sold 47,806 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $0.84, for a transaction totalling $40,157.04. Following the completion of the sale, the insider now directly owns 925,400 shares of the company's stock, valued at $777,336. Learn More on Mark E. Dmytruk's trading history.
Who are Ginkgo Bioworks' active insiders?: Ginkgo Bioworks' insider roster includes Barry Canton (Major Shareholder), Marijn Dekkers (Director), Mark Dmytruk (Insider), Christian Henry (Director), Jason Kelly (Insider), Reshma Shetty (Insider), and Harry Sloan (Director). Learn More on Ginkgo Bioworks' active insiders.
Are insiders buying or selling shares of Ginkgo Bioworks?: In the last twelve months, Ginkgo Bioworks insiders bought shares 1 times. They purchased a total of 297,619 shares worth more than $270,833.29. In the last twelve months, insiders at the sold shares 21 times. They sold a total of 1,314,797 shares worth more than $1,646,026.06. The most recent insider tranaction occured on October, 4th when insider Steven P Coen sold 306 shares worth more than $2,555.10. Insiders at Ginkgo Bioworks own 9.7% of the company. Learn More about insider trades at Ginkgo Bioworks.
Information on this page was last updated on 10/4/2024.

Mark E. Dmytruk Insider Trading History at Ginkgo Bioworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2024	Sell	47,806	$0.84	$40,157.04	925,400
4/2/2024	Sell	51,169	$1.05	$53,727.45	865,079
2/2/2024	Sell	39,569	$1.21	$47,878.49	761,737
12/4/2023	Sell	42,402	$1.39	$58,938.78	676,844
10/2/2023	Sell	42,237	$1.76	$74,337.12	586,393
9/5/2023	Sell	41,417	$2.23	$92,359.91	543,585
8/2/2023	Sell	46,519	$2.07	$96,294.33	499,959
7/3/2023	Sell	40,637	$1.80	$73,146.60	461,432
6/2/2023	Sell	40,511	$1.56	$63,197.16	417,028
5/22/2023	Sell	250,000	$1.50	$375,000.00	372,495
4/10/2023	Sell	740	$1.33	$984.20	576,254
3/15/2023	Sell	29,762	$1.31	$38,988.22	530,736
1/4/2023	Sell	34,588	$1.56	$53,957.28	454,549
11/3/2022	Sell	30,604	$2.65	$81,100.60	384,074

Mark E. Dmytruk Buying and Selling Activity at Ginkgo Bioworks

Ginkgo Bioworks Company Overview

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $7.17

$6.50

$7.35

50 Day Range

MA: $7.82

$6.23

$9.38

2 Week Range

Now: $7.17

$5.26

$75.20

Volume

1,216,371 shs

Average Volume

1,150,836 shs

Market Capitalization

$398.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Download Our Tesla Ebook For Free

From DTI | Ad

To claim your copy free of charge simply follow this link.

Mark Dmytruk Biography and Net Worth

What is Mark E. Dmytruk's net worth?

How old is Mark E. Dmytruk?

What is Mark E. Dmytruk's salary?

How do I contact Mark E. Dmytruk?

Has Mark E. Dmytruk been buying or selling shares of Ginkgo Bioworks?

Who are Ginkgo Bioworks' active insiders?

Are insiders buying or selling shares of Ginkgo Bioworks?